Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Detemir vs Semilente MC in Children with T1D
NCT00184639Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2004
- Primary completion
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin detemir in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Fasting Plasma Glucose at 32 weeks. Started Aug 2004; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00184639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184639.